Day: September 8, 2020

TEL AVIV, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced that the first patient has been dosed in the Phase 1/2 clinical trial of NT219, a dual inhibitor, novel small molecule targeting IRS1/2 and STAT3, important oncogenic drivers and major drug resistance pathways in many hard-to-treat cancers.“The dosing of the first patient in this important study represents a significant milestone for Kitov,” said Bertrand Liang, M.D., Ph.D., Chief Medical Officer of Kitov. “Based on the encouraging pre-clinical data generated by NT219 as both monotherapy and in combination with several anti-cancer drugs, we believe that this promising drug candidate has the potential to...

OMER, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — Medigus Ltd. (NASDAQ:MDGS) (TASE:MDGS), a technology company developing minimally invasive tools and an innovator in direct visualization technology, today announced that it was informed by ScoutCam, Inc. (OTC: SCTC), Medigus’ subsidiary and a leading developer and manufacturer of customized visual solutions and supplementary technologies, that ScoutCam has been officially included on a Fortune 500 multinational healthcare corporation’s Approved Supplier List (ASL). The qualification will allow ScoutCam to develop, manufacture and supply a complete visualization solution for the global company’s minimally invasive surgical product, which incorporates ScoutCam’s single-use miniature video cameras.“We are extremely excited not only for the recognition of our superior technology, but...

Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed in subjects on placebo added to background drug therapy, achieving median ACR CRISS score of 0.88784% of enrolled subjects were receiving background immunosuppressive drugs, reflecting recent trends in clinical practiceLenabasum treatment was safe and well-tolerated in this study with no new safety signals observedFurther analyses of data are underway, and results will be presented at upcoming medical conferencesLenabasum clinical trials in cystic fibrosis, dermatomyositis and systemic lupus erythematosus are ongoingCompany to host conference call and webcast today, September 8, 2020 at 8:30 a.m. ETNorwood, MA, Sept. 08, 2020 (GLOBE NEWSWIRE)...

NESS ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies (NASDAQ: SLGL), (“Sol-Gel”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the company will present at the following upcoming virtual investor conferences.Dr. Alon Seri-Levy, Sol-Gel’s Chief Executive Officer, will provide an overview of the Company and give a business update.  A live webcast of the presentation will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com. An archived webcast recording of the event will be available on the website for approximately 30 days.About Sol-Gel TechnologiesSol-Gel is a clinical-stage dermatology company focused...

NEWTOWN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the publication of an important, peer-reviewed study titled Translingual Neural Stimulation with the Portable Neuromodulation Stimulator (PoNS™) Induces Structural Changes Leading to Functional Recovery in Patients with Mild-to-Moderate Traumatic Brain Injury. The study was published in the peer reviewed journal EMJ Radiology. 2020;1[1]:64-71.Traumatic brain injury (“TBI”) of varying severity can result in balance and movement disorders, for which the benefits of treatment with physical therapy has limits. In this study, a 9 patient subset of the original 43 patients published in “Translingual Neurostimulation for the Treatment...

GREENWICH, Conn., Sept. 08, 2020 (GLOBE NEWSWIRE) —  XPO Logistics, Inc. (NYSE: XPO), the largest provider of last mile logistics for heavy goods in North America, today announced the appointment of Erik Caldwell as president of its last mile business unit. Caldwell has P&L responsibility for XPO’s last mile operations in the US and Canada. The unit manages more than 10 million home deliveries and installations of big and bulky products annually, including appliances, exercise equipment and furniture.Caldwell has 16 years of executive experience with retail and industrial supply chains. He joined XPO in 2017 as chief operating officer, supply chain – Americas and Asia Pacific. Previously, Caldwell was senior vice president, supply chain and digital operations with Hudson’s Bay Company; senior vice president, global Rx...

SAN FRANCISCO, Sept. 08, 2020 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) announced the appointment of Percy Carter, MBA, PhD, to the newly-created position of Chief Scientific Officer, where he will lead FibroGen’s research efforts, leveraging more than 20 years of global biopharmaceutical leadership and experience.“Great science and innovation are the backbone of FibroGen and what enable us to develop transformational medicines for patients. With Percy’s leadership, we will continue our legacy of biological breakthroughs and advancing first-in-class therapeutics,” said Enrique Conterno, Chief Executive Officer, FibroGen. “Percy’s expertise and experience make him the ideal person to lead FibroGen’s scientific agenda. I look forward to his leadership impact on advancing our unique position in both hypoxia-inducible factor...

HOUSTON, Sept. 08, 2020 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology company developing transformative therapeutics, today announced that the Company will present and conduct one-on-one meetings at the following two virtual investor conferences in September:Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 15, 2020, at 3:20 p.m. ETH.C. Wainwright 22nd Annual Global Investment Conference on Wednesday, September 16, 2020, at 1:00 p.m. ETLive webcasts and audio archives of the presentations will be available at http://ir.aravive.com. Archived replays of the webcasts will be available for 90 days following the presentations.About AraviveAravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases....

Press releaseSynairgen plc(‘Synairgen’ or the ‘Company’)Synairgen announces positive data from interim analysis of SNG001 trial in COPD patientsSNG001 well tolerated in this older population with a significant co-morbidity (COPD)Strong interferon driven antiviral biomarker response Data support future progression of SNG001 for exacerbating COPD patients Positive data supportive of SNG001 COVID-19 programmeSouthampton, UK – 8 September 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces positive data from the interim analysis of its exploratory Phase II clinical trial of inhaled SNG001 in Chronic Obstructive Pulmonary Disease (COPD) patients with a confirmed respiratory viral infection.Key findings      ·SafetySNG001 was well tolerated during the treatment period in a study population...

CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered, systemically acting biologics, today announced that management will participate in two upcoming virtual investor conferences in September:Morgan Stanley 18th Annual Global Healthcare Conference. Management will host a fireside chat at 4:30 p.m. ET on Monday, September 14, 2020.Cantor Fitzgerald’s Virtual Global Healthcare Conference 2020. Management will participate in 1×1 meetings on Thursday, September 17, 2020.A live audio webcast of the Morgan Stanley fireside chat will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following...